Cathérine Reenaers

2.6k total citations
63 papers, 1.1k citations indexed

About

Cathérine Reenaers is a scholar working on Epidemiology, Genetics and Immunology. According to data from OpenAlex, Cathérine Reenaers has authored 63 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Epidemiology, 50 papers in Genetics and 16 papers in Immunology. Recurrent topics in Cathérine Reenaers's work include Inflammatory Bowel Disease (49 papers), Microscopic Colitis (42 papers) and Autoimmune and Inflammatory Disorders (22 papers). Cathérine Reenaers is often cited by papers focused on Inflammatory Bowel Disease (49 papers), Microscopic Colitis (42 papers) and Autoimmune and Inflammatory Disorders (22 papers). Cathérine Reenaers collaborates with scholars based in Belgium, France and United States. Cathérine Reenaers's co-authors include Édouard Louis, Jacques Bélaïche, Catherine Van Kemseke, Filip Baert, Fernand Fontaine, Paul Meunier, Laurence Seidel, Olivier Dewit, Marie‐Alice Meuwis and Peter Bossuyt and has published in prestigious journals such as Gastroenterology, Gut and World Journal of Gastroenterology.

In The Last Decade

Cathérine Reenaers

59 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cathérine Reenaers Belgium	19	835	671	320	222	101	63	1.1k
Reena Khanna Canada	21	969 1.2×	760 1.1×	264 0.8×	442 2.0×	78 0.8×	39	1.2k
G. D’Haens Netherlands	12	985 1.2×	851 1.3×	380 1.2×	211 1.0×	47 0.5×	37	1.2k
Wendy Kampman United States	4	771 0.9×	650 1.0×	207 0.6×	201 0.9×	52 0.5×	8	903
B Huang Canada	9	893 1.1×	770 1.1×	269 0.8×	199 0.9×	42 0.4×	32	1.0k
Hanzhe Zheng United States	6	717 0.9×	572 0.9×	187 0.6×	214 1.0×	40 0.4×	13	895
Yinghua Lang United States	9	1.2k 1.5×	974 1.5×	431 1.3×	303 1.4×	39 0.4×	15	1.4k
Mark R. Fleisher United States	10	674 0.8×	520 0.8×	220 0.7×	429 1.9×	60 0.6×	17	1.2k
Matthias Jürgens Germany	11	630 0.8×	443 0.7×	162 0.5×	391 1.8×	54 0.5×	19	884
Amy Marren United States	10	589 0.7×	328 0.5×	209 0.7×	331 1.5×	40 0.4×	26	919
Taku Kobayashi Japan	12	522 0.6×	332 0.5×	201 0.6×	361 1.6×	110 1.1×	41	903

Countries citing papers authored by Cathérine Reenaers

Since Specialization

Citations

This map shows the geographic impact of Cathérine Reenaers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cathérine Reenaers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cathérine Reenaers more than expected).

Fields of papers citing papers by Cathérine Reenaers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cathérine Reenaers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cathérine Reenaers. The network helps show where Cathérine Reenaers may publish in the future.

Co-authorship network of co-authors of Cathérine Reenaers

This figure shows the co-authorship network connecting the top 25 collaborators of Cathérine Reenaers. A scholar is included among the top collaborators of Cathérine Reenaers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cathérine Reenaers. Cathérine Reenaers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moens, Annick, Tom Holvoet, Patrick M. Bossuyt, et al.. (2025). P1008 Subcutaneous infliximab in IBD patients previously treated with an optimized intravenous infliximab dosing schedule: preliminary results on expectations and satisfaction of switching from intravenous to subcutaneous infliximab. Journal of Crohn s and Colitis. 19(Supplement_1). i1866–i1867. 1 indexed citations

Pierre, Nicolas, Vân Anh Huynh‐Thu, Dominique Baiwir, et al.. (2024). Serum proteome signatures associated with ileal and colonic ulcers in Crohn's disease. Journal of Proteomics. 302. 105199–105199.

Reenaers, Cathérine, Maria Nachury, David Laharie, et al.. (2024). DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort. Journal of Crohn s and Colitis. 18(Supplement_1). i117–i117. 1 indexed citations

Reenaers, Cathérine, Maria Nachury, David Laharie, et al.. (2024). Impact of Histological Remission for Predicting Clinical Relapse in Crohn’s Disease: A Post Hoc Analysis of the Prospective STORI Cohort. Journal of Crohn s and Colitis. 19(4). 1 indexed citations

Outtier, An, Édouard Louis, Olivier Dewit, et al.. (2024). Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study. Clinical Gastroenterology and Hepatology. 22(12). 2468–2474.e1. 5 indexed citations

Reenaers, Cathérine, et al.. (2022). Early Post-Operative Endoscopy Is Associated with Lower Surgical Recurrence of Crohn’s Disease: A Retrospective Study of Three Successive Cohorts. Gastroenterology Research and Practice. 2022. 1–9. 3 indexed citations

Amiot, Aurélien, Anne Bourrier, Jean‐Marc Gornet, et al.. (2022). Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study. Infection Prevention in Practice. 5(1). 100267–100267. 1 indexed citations

Monin, Leticia, Séverine Dubois, Cathérine Reenaers, et al.. (2020). Ustekinumab in bio-naïve and bio-failure Crohn's disease patients: Results from a « real-life » monocentric cohort.. Digestive and Liver Disease. 53(1). 72–78. 15 indexed citations

Pouillon, Lieven, Thomas Rémen, Édouard Louis, et al.. (2020). Risk of Late Postoperative Recurrence of Crohn’s Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers. Clinical Gastroenterology and Hepatology. 19(6). 1218–1225.e4. 11 indexed citations

10.

Gagnière, Charlotte, Anne Bourrier, Philippe Seksik, et al.. (2018). Risk of serious infection in healthcare workers with inflammatory bowel disease: a case‐control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Alimentary Pharmacology & Therapeutics. 48(7). 713–722. 7 indexed citations

11.

Reenaers, Cathérine, Peter Bossuyt, P. Hindryckx, et al.. (2018). Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterology Journal. 6(8). 1117–1125. 48 indexed citations

12.

Vos, Martine De, Séverine Vermeire, Édouard Louis, et al.. (2017). Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. United European Gastroenterology Journal. 6(3). 439–445. 14 indexed citations

13.

Baert, Filip, Cathérine Reenaers, Peter Bossuyt, et al.. (2017). P438 Adalimumab dose escalation and de-escalation in ulcerative colitis: incidence and predictors of success. A real life Belgian cohort study. Journal of Crohn s and Colitis. 11(suppl_1). S299–S299. 1 indexed citations

14.

Reenaers, Cathérine, et al.. (2016). Long-term evolution and predictive factors of mild inflammatory bowel disease. Scandinavian Journal of Gastroenterology. 51(6). 712–719. 11 indexed citations

15.

Louis, Édouard, Iris Dotan, Subrata Ghosh, et al.. (2015). Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations: Table 1.. Journal of Crohn s and Colitis. 9(8). 685–691. 56 indexed citations

16.

Meuwis, Marie‐Alice, et al.. (2013). Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Gut. 62(12). 1806–1816. 79 indexed citations

17.

Bélaïche, Jacques, et al.. (2011). Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. Journal of Crohn s and Colitis. 5(3). 196–202. 23 indexed citations

18.

Louis, Édouard, Cathérine Reenaers, & Jacques Bélaïche. (2008). Does the behavior of Crohnʼs disease change over time?. Inflammatory Bowel Diseases. 14. S54–S55. 3 indexed citations

19.

Louis, Édouard, Jacques Bélaïche, & Cathérine Reenaers. (2008). Are we giving biologics too much time? When should we stop treatment?. World Journal of Gastroenterology. 14(36). 5528–5528. 5 indexed citations

20.

Reenaers, Cathérine, et al.. (2007). Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohnʼs disease with normal C-reactive protein serum level. Inflammatory Bowel Diseases. 13(9). 1100–1105. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact